Market Overview

Data Shows Medical Cannabis Could Reach USD 19 Billion in Sales by 2027

Share:

Data Shows Medical Cannabis Could Reach USD 19 Billion in Sales by 2027

FinancialBuzz.com News Commentary

PR Newswire

NEW YORK, August 27, 2018 /PRNewswire/ --

Data published by Arcview Market Research, in partnership with BDS Analytics, indicates that the worldwide consumer spending on legal cannabis is projected to reach USD 57 Billion by 2027, with adult-use cannabis making up the majority of spending, totaling USD 38.3 Billion, while medical spending will reach USD 19.1 Billion. The report explains that while the adult-use market is expected to dominate in North America, the medical market will have advantages overseas due to government-subsidized health systems covering the cost for patients. Europe for example, which has a population of about 739 Million people and more than USD 1.5 Trillion in health care spending, has the potential to be the largest medical cannabis market in the world. Tidal Royalty Corp. (OTC:TDRYF), CannaRoyalty Corp. (OTC:CNNRF), VIVO Cannabis Inc. (OTC:VVCIF), Auxly Cannabis Group Inc. (OTC:CBWTF), GW Pharmaceuticals plc (NASDAQ:GWPH)

Focusing on the United States, the legal cannabis market is projected to reach USD 11 Billion in consumer spending in 2018. Arcview Market Research and BDS Analytics report that according to SOLMM6, despite federal prohibition the U.S. legal cannabis industry experienced 31% growth in 2017 and has reached USD 8.5 Billion in spending. Arcview forecasts that the continuing state-by-state roll-out of medical-use programs and then adult-use legalization, will bring nationwide spending in the U.S. to USD 23.4 billion in 2022, growing at a 22% compound annual growth rate over that five-year forecast period. "The end of marijuana prohibition is in sight and what that means for this market cannot be overstated," said Troy Dayton, CEO of the Arcview Group. "There are billions of dollars in institutional capital chomping at the bit to take advantage of this shift, but so far haven't found a major way in. This leaves a limited window for businesses to get a foothold and build value for liquidity events that might come sooner than any of us thought possible just a few months ago."

Tidal Royalty Corp. (OTC:TDRYF) is also listed on the Canadian Securities Exchange under the ticker (CSE:RLTY). Just earlier today the company announced breaking cannabis news that, "it has entered into a binding letter of intent ("Agreement") to acquire certain assets that are strategic to Tidal Royalty from CannaRoyalty Corp. (CSE:CRZ) (OTC:CNNRF) ("CannaRoyalty"), a leading North American cannabis products and brands company.

Pursuant to the Agreement, Tidal Royalty will acquire a royalty entitlement and equity interest in Alternative Medical Enterprises, LLC, doing business as AltMed, ("AltMed") a leading multi-state, vertically-integrated operator. The aggregate consideration for the acquisition is C$8 million, in a combination of cash and Tidal Royalty's stock.

AltMed is led by former senior pharmaceutical executives and has captured market share by implementing pharma industry standards to the development, production and dispensing of medical cannabis. AltMed has vertically-integrated operations in both Florida and Arizona, pursuant to such states' regulated cannabis programs, and currently has applications for licenses pending in Ohio. In addition to distributing its own award-winning product line (MüV™) of topicals, gels, concentrates and transdermal patches, AltMed has distribution partnerships with leading cannabis brands - including with Wana Brands, a leading producer of cannabis-infused products.

Pursuant to the Agreement, Tidal Royalty will acquire a royalty on U.S. and international sales of the MüV™ product line. Tidal Royalty will also acquire an equity interest in AltMed.

"We've been following AltMed for quite some time now and have watched them expand their footprint very strategically and methodically. They are led by an extremely entrepreneurial and capable management team and we feel that they are positioned to be a leading player in the U.S. industry. We are excited to be in this position and look forward to finding additional ways that we can support their growth plans," said Paul Rosen, CEO & Chairman of Tidal Royalty. "This transaction was really made possible by our strong synergistic relationship with CannaRoyalty, a company whom we have a great deal of respect and admiration for. We are confident that our companies will identify additional mutually-strategic opportunities in the emerging U.S. regulated cannabis industry."

"This Agreement advances our stated strategy of realizing value for shareholders on non-core assets. The gains from our successful investment in AltMed will provide CannaRoyalty with capital to continue to expand its distribution and brand network in the California market. We are confident that AltMed will be a valuable addition to Tidal Royalty's portfolio, and as CannaRoyalty continues to grow and build a solid presence in California, we look forward to opportunities to partner with the experienced team at Tidal Royalty," said Marc Lustig, Chairman and CEO of CannaRoyalty.

Closing of the transaction is subject to, among other things, the satisfactory completion of due diligence, which is currently underway, and the receipt of all corporate and regulatory approvals. With the execution of this Agreement, Tidal Royalty has now entered into letters of intent with cannabis operators in Florida, Arizona, California, Nevada, Massachusetts and Illinois. In addition, Tidal Royalty is in the process of evaluating multiple additional opportunities across the U.S., including in New York, Ohio, Pennsylvania, Texas and Michigan. Tidal Royalty intends to provide further information on those discussions when the respective parties reach an agreement and execute letters of intent.

About Tidal Royalty - Tidal Royalty provides royalty financing to the U.S. regulated cannabis industry. Led by an executive team with extensive industry experience in Canada and the U.S., Tidal Royalty provides operators with the funding they need to grow their business. Operators benefit from non-dilutive capital and investors get top-line access to a diversified portfolio of companies that will form the future of this transformative industry.

CannaRoyalty Corp. (OTCQX:CNNRF) is a North American cannabis consumer product company currently focused on building a leading distribution business in California, the world's largest regulated cannabis market. Recently, the Company announced its financial results for the three and six-month periods ended June 30th, 2018. Revenue for Q2 2018 was USD 3.5 Million compared to USD 643,437 in Q1 2018. On August 9th, 2018, CannaRoyalty announced the close of Aurora's acquisition of Anandia Inc. for initial consideration valued at approximately USD 115 Million in common shares and warrants of Aurora. CannaRoyalty's equity stake in Anandia was reported at approximately USD 26.4 Million as of June 30th, 2018. On August 14th, 2018, the Company's previously announced (July 11th) sale of its Canadian pre-roll technology license to Aurora for aggregate consideration of USD 7 Million in Aurora common shares, had closed.

VIVO Cannabis Inc. (OTCQB:VVCIF) holds production and sales licenses from Health Canada and its world-class indoor cultivation facility in Napanee, Ontario contains proprietary plant-growing technology. VIVO is expanding its production capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, including Germany, Australia and Israel. Recently, the Company announced that it has completed an agreement with the Ontario Cannabis Store ("OCS") to supply the province with high-quality cannabis products. Under the terms of the agreement, VIVO will supply the Ontario market with 16 cannabis products to meet demand in the adult-use recreational cannabis market, set to open on October 17th, 2018.

Auxly Cannabis Group Inc. (OTCQX:CBWTF) is a collective of entrepreneurs with a passion for the cannabis industry past, present and future. Recently, the Company announced that it has entered into a share purchase agreement with KGK Science Inc. to acquire all of the issued and outstanding shares of KGK for total consideration of USD 12,300,000 payable in cash and common shares of the Company. KGK Science is the leading contract research organization offering clinical trial services and regulatory consulting for the cannabis, dietary supplement, functional food, beverage, ingredient and cosmetic industry. The Company expects to leverage KGK's expertise and research abilities to further the Company's product development efforts through collaboration with the Company's wholly owned subsidiary, Dosecann Inc. For nearly two decades, KGK has served many of North America's leading nutraceutical, natural health product and consumer packaged goods companies such as Kraft Foods, Sanofi, Nature's Bounty, and NuSkin.

GW Pharmaceuticals plc (NASDAQ:GWPH) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. Earlier this year, the Company announced that the U.S. Food and Drug Administration (FDA) has approved EPIDIOLEX® (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. EPIDIOLEX is the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs (AEDs). Product availability is pending rescheduling which is expected to occur within 90 days. EPIDIOLEX, the first prescription, plant-derived cannabinoid medicine in the United Statesand the first in a new class of anti-epileptic medications, is a pharmaceutical formulation of pure cannabidiol (CBD) now FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older, pending DEA rescheduling.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Tidal Royalty Corp. financial news dissemination and PR services, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

For further information:

info@financialbuzz.com 

+1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com

View Comments and Join the Discussion!